Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 17;16(12):2238.
doi: 10.3390/cancers16122238.

Arterial Thrombosis in Patients with Cancer

Yan Xu  1 , Marc Carrier  1 , Miriam Kimpton  1
Affiliations
Review

Arterial Thrombosis in Patients with Cancer

Yan Xu et al. Cancers (Basel). .

Abstract

Patients with cancer are at increased risk of arterial thromboembolic disease due to the presence of risk factors common to both the development of cancer and arterial thrombosis, the cancer itself, and the treatments provided to treat cancer. We review here the epidemiology and pathophysiology of arterial thromboembolic disease in cancer, along with its prevention and treatment strategies. We also propose a generalized approach for the management of arterial thromboembolic disease in this patient population.

Keywords: arteries; embolism and thrombosis; neoplasms.

PubMed Disclaimer

Conflict of interest statement

M. Kimpton and Y. Xu do not have any conflicts of interest. M. Carrier reports grants from Leo Pharma and Pfizer, and personal fees from BMS, Leo Pharma, Bayer, Pfizer, Servier, Valeo, and Sanofi.

References

    1. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of Arterial Thromboembolism in Patients with Cancer. J. Am. Coll. Cardiol. 2017;70:926–938. doi: 10.1016/j.jacc.2017.06.047. - DOI - PMC - PubMed
    1. Mulder F.I., Horvath-Puho E., van Es N., Pedersen L., Buller H.R., Botker H.E., Sorensen H.T. Arterial Thromboembolism in Cancer Patients: A Danish Population-Based Cohort Study. JACC CardioOncol. 2021;3:205–218. doi: 10.1016/j.jaccao.2021.02.007. - DOI - PMC - PubMed
    1. Khorana A.A., Soff G.A., Kakkar A.K., Vadhan-Raj S., Riess H., Wun T., Streiff M.B., Garcia D.A., Liebman H.A., Belani C.P., et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N. Engl. J. Med. 2019;380:720–728. doi: 10.1056/NEJMoa1814630. - DOI - PubMed
    1. van Doormaal F.F., Di Nisio M., Otten H.-M., Richel D.J., Prins M., Buller H.R. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011;29:2071–2076. doi: 10.1200/JCO.2010.31.9293. - DOI - PubMed
    1. Alexander M., Harris S., Underhill C., Torres J., Sharma S., Lee N., Wong H., Eek R., Michael M., Tie J., et al. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial. JAMA Oncol. 2023;9:1536–1545. doi: 10.1001/jamaoncol.2023.3634. - DOI - PMC - PubMed

LinkOut - more resources